Comparative Pharmacology
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPRELSA versus NILOTINIB HYDROCHLORIDE.
CAPRELSA vs NILOTINIB HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and oncogenesis, including VEGFR2, EGFR, and RET.
Bcr-Abl tyrosine kinase inhibitor; specifically binds to and inhibits the kinase activity of Bcr-Abl, leading to inhibition of proliferation and induction of apoptosis in Bcr-Abl positive cells.
300 mg orally once daily, with or without food.
400 mg orally twice daily, approximately 12 hours apart, with food.
None Documented
None Documented
Terminal half-life approximately 90 hours (range 30–150 hours), supporting once-daily dosing; steady-state achieved by day 15.
Terminal elimination half-life is approximately 17 hours (range 15-22 hours), supporting twice-daily dosing.
Primarily fecal (approximately 75% of administered dose, mainly as unchanged drug and metabolites); renal excretion accounts for about 25% (less than 1% unchanged).
Primarily fecal (≥90%); renal excretion accounts for <5% as unchanged drug and metabolites.
Category C
Category D/X
Kinase Inhibitor
Kinase Inhibitor